"Anilides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any aromatic amide obtained by acylation of aniline.
| Descriptor ID |
D000813
|
| MeSH Number(s) |
D02.065.199 D02.092.146.113
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anilides".
Below are MeSH descriptors whose meaning is more specific than "Anilides".
This graph shows the total number of publications written about "Anilides" by people in this website by year, and whether "Anilides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 12 | 18 |
| 2018 | 13 | 15 | 28 |
| 2019 | 2 | 8 | 10 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anilides" by people in Profiles.
-
The Effects of Insulin-Like Growth Factor I and BTP-2 on Acute Lung Injury. Int J Mol Sci. 2021 May 15; 22(10).
-
Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment. J Am Acad Dermatol. 2020 06; 82(6):e205.
-
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. J Clin Oncol. 2019 12 01; 37(34):3275-3282.
-
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019 09; 4(9):721-730.
-
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019 09 01; 79(17):4326-4330.
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.
-
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. Eur J Gastroenterol Hepatol. 2019 04; 31(4):534-539.
-
PPAR? inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med. 2019 05; 23(5):3724-3736.
-
Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019 04; 33(4):e145-e147.